Despite substantial interest and investigation during the past 10 years, fibromyalgia continues to provoke many controversies. The major issues discussed in this review include the diagnostic utility of fibromyalgia, psychiatric and central nervous system factors, therapy and outcome, and compensation and disability. It is important to recognize the psychosocial factors that distinguish patients with fibromyalgia from persons in the community who meet criteria for the syndrome but who do not seek medical care. Such factors may be among the most important in long-term treatment.
Since 1987, when my first review on fibromyalgia (FM) syndrome was published,1 more than 1000 articles on FM have appeared in peer-reviewed journals. Some reports2 suggest that little progress has been made in understanding or treating this disorder. Indeed, the concept of FM remains controversial, and many authors3,4 continue to challenge its existence and diagnostic utility. To review what we have learned about FM during the past decade, I have formulated a series of questions: How has FM been defined? How and when should FM be diagnosed? What is the association between FM and psychiatric illness? Have pathophysiological abnormalities or causes been identified? Can FM be effectively treated? What are the outcome and prognosis? Can FM cause disability? Is the diagnosis of FM useful? I will attempt to answer these questions from my research and experience and a detailed analysis of key investigations reported during the past 10 years.
Between 10% and 12% of the general population has chronic widespread pain.5,6 Women are affected more than men, and the prevalence of widespread pain increases with age.6 Many persons with chronic musculoskeletal pain do not have a well-defined musculoskeletal disease. The construct of FM was designed to account for persons with such generalized, persistent idiopathic pain.1,7,8 As with any syndrome, the diagnosis of FM is based on a set of predefined symptoms. The mandatory symptom is widespread pain not explained by an inflammatory or degenerative musculoskeletal disorder. There are no "objective markers" of disease. The presence of many tender points in soft tissue locations validates the diagnosis.
Various diagnostic criteria for FM were proposed9,10 and field tested. The 1990 American College of Rheumatology classification criteria8 for FM have been adopted by most investigators in the past 10 years. In that study, 293 consecutive patients with FM were compared with 265 control patients who had regional chronic musculoskeletal pain or a systemic rheumatic disease. Training sessions were used to increase interrater reliability, and independent blinded assessors recorded the history and performed the physical examination. The symptom of widespread pain and the finding of mild or greater tenderness in at least 11 of 18 specified tender points on digital palpation provided a sensitivity of 88% and specificity of 81% in distinguishing FM from other causes of chronic musculoskeletal pain. The American College of Rheumatology study committee found no difference in patients with FM who had a concurrent medical condition. Therefore, in regard to classification criteria,8 no distinction is made as to comorbid illness or possible associated trauma. Using current classification criteria,6,11 the estimated prevalence of FM in the general community is 2% for both sexes, 3.4% for women, and 0.5% for men. The prevalence increases with age, reaching greater than 7% in women aged 60 to 79 years.6 Fibromyalgia is the second most common diagnosis in rheumatology clinics.12
The finding of multiple tender points on physical examination does not correlate with any specific muscle or soft tissue disease but, rather, reflects generalized heightened pain perception.11,13,14 Patients with FM are excessively tender at many musculoskeletal and nonmusculoskeletal sites. Nevertheless, the tender-point examination is clinically reliable8,15-18 in discriminating patients with FM from those with other rheumatic conditions. The presence of many tender points correlates with depression, fatigue, anxiety, and somatic symptoms as well as with pain.6,11 Wolfe19 suggested that the tender-point count functions like a sedimentation rate for distress in patients with chronic pain. The presence of multiple tender points and the severity of widespread pain reflects the continuum of pain in persons in the community not seeking medical care. There is no clear boundary between endemic pain in persons in the community and the pain of FM.
Operational diagnostic criteria for any illness lacking definitive pathophysiological abnormalities can be criticized as being arbitrary. Expert opinion is the diagnostic criterion standard, with the potential of leading to circular reasoning or tautology.20 Nevertheless, the diagnosis of many chronic illnesses, including migraine and tension headaches, irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), and depression, is based on similarly subjective criteria determined by a consensus of experienced clinicians.
How and when should fm be diagnosed?
The classification criteria for FM were established to provide investigators with a homogeneous group of patients to study. Classification criteria are not designed for diagnosing disease in individual patients. In clinics, FM is diagnosed similarly to migraine or muscular headaches. Using simple questions about pain or pain diagrams, one can reliably distinguish patients who are likely to have FM and unlikely to have an inflammatory joint disease.21 A careful history taking and physical examination, however, are necessary to differentiate FM from rheumatoid arthritis, osteoarthritis, and other systemic illnesses. The patient should have chronic widespread pain, fatigue, and associated symptoms such as sleep disturbances and headaches. The findings of a physical examination are usually normal except for multiple tender points. A minimal number of laboratory tests, such as an erythrocyte sedimentation rate and thyroid function tests, are recommended. In 1987,1 I described the typical patient with FM as a younger woman with no other ongoing medical disorder. In the past decade, however, it has become apparent that the prevalence of FM increases with age and that FM is commonly associated with comorbid disorders.6
The diagnosis of FM is not as straightforward in patients with concurrent medical or psychiatric illnesses. In such patients, clinicians must be confident that the FM construct explains the patient's symptoms. Such confidence can only be gained after considerable experience evaluating patients with chronic pain.22 Some rheumatic disorders with subtle findings on examination, such as the spondyloarthropathies, may be misdiagnosed as FM.23 Fibromyalgia may coexist with osteoarthritis, and, in elderly patients, it is often mistakenly diagnosed as osteoarthritis. Osteoarthritis, however, generally causes pain on joint movement and generally not widespread constant pain. Fibromyalgia is present in 10% to 40% of patients with systemic lupus erythematosus (SLE) and in 10% to 30% of patients with rheumatoid arthritis.24-26 It may be difficult to determine whether patients with rheumatoid arthritis are having an exacerbation of their arthritis or if their symptoms are related to concurrent FM. In such patients, a consultation with an experienced clinician is more cost-effective than ordering several blood tests, radiographs, and imaging studies.
Fibromyalgia may also mimic systemic diseases such as Lyme disease and SLE. Twenty-five percent to 50% of patients referred to Lyme disease clinics never had Lyme disease but, rather, had FM.27,28 It is not cost-effective to obtain Lyme serologic tests on such patients and certainly not cost-effective to treat such patients empirically with antibiotics.28,29 Approximately 25% of patients referred for possible SLE to a rheumatology clinic had FM and antinuclear antibodies but no other manifestations of SLE.30 These patients should not be diagnosed as having and treated for SLE. Patients with FM may also present with symptoms that suggest degenerative disc disease or nerve entrapment syndromes.
Fibromyalgia often coexists with other common, ill-defined syndromes such as CFS, headache syndromes, IBS, and depression. Based on standard classification criteria, 50% to 70% of patients with FM have a current or past diagnosis of CFS, IBS, migraine, and depression.31-33 Each of these disorders has similar symptoms, chronicity, demographics, and therapies. Each of these syndromes also may be associated with a vast array of symptoms, such as facial pain, paresthesias, urinary urgency, sicca symptoms, Raynaud phenomenon, and dysmenorrhea, adding to the diagnostic confusion. These syndromes overlap so extensively that it may be concluded that each represents different presentations of the same general condition.31,34,35 Therefore, little value exists in worrying whether a patient has FM, CFS, or IBS—or all 3 disorders.
What is the association between fm and psychiatric illness?
There is strong evidence31 that major depression is associated with FM. The symptoms of fatigue, sleep disturbances, and cognitive disturbances that are characteristic of FM are also present in depressive illness. Comorbid disorders, such as migraine and muscular headaches, CFS, IBS, premenstrual syndrome, and atypical facial pain, are prominent in both FM and depression.31,32 Patients with FM, as well as patients with these related disorders, often improve with antidepressant medications.36,37 A lifetime history of depression has been reported31,32 in 50% to 70% of patients with FM. Current major depression, however, was found in only 18% to 36% of patients with FM. Ahles et al38 and Yunus and colleagues39 did not find a greater prevalence of major depression in patients with FM than in those with rheumatoid arthritis and in healthy controls. Therefore, even in tertiary referral clinics, most patients with FM do not have a current psychiatric illness.
The overlap of symptoms, patterns of comorbidity, family history studies, response to various antidepressant medications, and similar results of neurohormonal studies all demonstrate an association of FM and depression. The nature of that association is controversial. Patients with FM may become depressed because of pain and disability. Conversely, major depression may cause FM, a classic psychosomatic theory. But most patients with FM are not depressed, and the variable temporal relationship of depression and pain militates against the theories.39 The association more likely relates to a sharing of common biological40 or psychological factors.41
Psychological stress has been found42-47 to influence the expression of pain and other core symptoms in FM, mood disorders, chronic headaches, CFS, and IBS. People who believed that emotional trauma was a precipitating event for their FM were more likely to become a patient in a specialty clinic and had greater health care use than those not identifying emotional trauma.45 Patients with FM and those with IBS who were observed in tertiary referral clinics had a substantially higher incidence of present and past psychiatric illness than those in the community with similar symptoms.45-47 In women with IBS, there was a higher incidence of sexual and physical abuse in childhood than in people in the community with IBS symptoms.44,47
Investigators from the University of Alabama Medical Center, Birmingham, have published a series of important observations45,46,48-51 comparing patients with FM observed by a rheumatologist with people in the community who meet criteria for having FM but who have not been given the diagnosis or treated for it ("FM nonpatients") (Table 1). The patients and nonpatients were then compared with healthy controls. The core symptoms of FM and objective measures of pain perception, including cerebrospinal levels of substance P and blood flow imaging of the thalamus and caudate nucleus, were similar in FM clinic patients and nonpatients. Significantly greater numbers of current and past psychiatric illnesses were found in the patients with FM (P=.002), but not in the nonpatients, compared with healthy controls. The current and past psychiatric illnesses were directly related to health-seeking behavior.46
Have pathophysiological abnormalities or causes been identified?
After more than a century of research52,53 that failed to detect consistent abnormalities in the muscle and other soft tissues in FM, investigations have turned toward the neurosciences.54 Patients with FM have a generalized hypervigilance to both pain and auditory stimuli.55 There is evidence for qualitatively altered nociception.56 The heightened pain response at tender points is now generally accepted to be a manifestation of altered central nervous system processing of nociceptive stimuli.57-59 Following electrocutaneous stimuli,57 patients with FM had diffuse regions of secondary hyperalgesia in the upper extremities. Levels of substance P and abnormal antinociceptive peptides are elevated in the cerebrospinal fluid of patients with FM.60,61 Brain imaging demonstrated substantially lower regional cerebral blood flow to the thalamus and caudate nucleus in women with FM compared with normal controls.48 The caudate nucleus and thalamus signal noxious stimuli, and decreased blood flow to these areas has been demonstrated in other chronic pain disorders. Studies of humans and of animals have noted that females have a lower pain threshold and tolerance and a higher sensitivity to various noxious stimuli.54
Slow-wave–sleep abnormalities in FM were initially reported in the early 1970s, and more recent studies62 suggest that they are prominent. The most frequent finding has been alpha intrusion in non–rapid-eye-movement sleep.62-64 These findings are not specific, however, and decreased sleep efficiency is present in children with FM and their mothers.63,64 Some studies also have found sleep apnea to be common in men with FM,65 and periodic leg movements have been reported in some studies.66,67
Research has also found68,69 alterations of various neurohormones in FM. There is exaggerated corticotropin response to corticotropin-releasing hormone and variable disturbances of sympathetic nervous system activity in FM. Low levels of somatomedin C, which reflects growth-hormone release, also have been noted70,71 in patients with FM. Evidence of sympathetic-parasympathetic imbalance,72,73 specifically related to neurally mediated hypotension, has been found in FM and CFS.
Evidence does not exist for a single causal agent in FM. Self-reports1,74-76 have identified physical trauma, emotional trauma, and infection as possible precipitating events in patients with this disorder. Despite the similarities of FM and CFS,33 clinical and serologic studies have not identified an etiologic role for the Epstein-Barr virus,33 parvovirus,77 or other viruses in either disorder.78 Certain infections such as Lyme disease may trigger FM.78 For example, 10% to 25% of patients with established Lyme disease had the development of FM that persisted for months or years after adequate treatment of Lyme disease.27,28,79,80 These patients do not respond to protracted or repeated courses of antibiotics but often receive such treatment at a substantial cost.28
Cervical spine pain,81 benign joint hypermobility,82,83 and steroid withdrawal84 also have been identified by some authors as contributing to the pathogenesis of FM. Fibromyalgia developed in 21% of persons who had a cervical spine injury but only 2% of those with a leg fracture.85 No patient had chronic pain before the trauma. Sex, genetic factors, and comorbid musculoskeletal disorders may each act as nociceptive amplifiers and contribute to the clinical syndrome.86
Can fm be effectively treated?
Possible useful variables to measure change in FM clinical trials87-90 have included self-reported pain, sleep, and global well-being as well as functional and psychological status. Tender-point counts and the alpha-slow-wave–sleep anomaly have not correlated well87,91,92 with symptoms or treatment response. Because of the cost of long-term clinical trials, more attention should focus on meta-analysis and N-of-1 trials.93,94
Randomized clinical trials95-98 published during the past decade have demonstrated some efficacy for central nervous system medications, cardiovascular fitness training,99 regional sympathetic block,100 electromyographic biofeedback,101 hypnotherapy,102 and electroacupuncture103 (Table 2). Medication therapy has produced meaningful improvement in 30% to 50% of patients. Tricyclic antidepressant medications, particularly amitriptyline hydrochloride, have been most often evaluated.95,96,98,104,105 The decrease in pain with the use of these medications has been significant but modest and tends to wane over time.104 Most trials have been of short duration, and the only study of at least 6 months' duration104 demonstrated a gradual loss of medication efficacy. Fluoxetine hydrochloride and amitriptyline were more effective than placebo in reducing FM symptoms, and the combination of both worked better than either alone.37 In other reports, however, there was no beneficial effect of fluoxetine106 or of a different serotonin reuptake inhibitor, citalopram,107 or of tenoxicam and bromazepam.108 Treatment with alprazolam combined with ibuprofen demonstrated modest improvement.109 Nonsteroidal anti-inflammatory drugs and corticosteroids,96,109,110 magnesium and malic acid,111 bright light,112S-adenosyl-L-methionine,113 and topical lidocaine hydrochloride in sphenopalatine blocks100 were not effective.
An aerobic exercise program has been more effective than simple relaxation or stretching.99,114,115 Enhanced cardiovascular fitness was achieved and sustained during these trials. The prognosis and outcome of FM and related conditions are adversely affected by inappropriate coping strategies and by catastrophic beliefs.116,117 Cognitive-behavior therapy is a logical approach to change such beliefs and has been proved an effective tool in FM and CFS.118-120 Cognitive-behavior and stress-reduction programs were helpful in patients when compared with historical or wait-listed controls.118,121 Group education improved the quality of life in patients with FM, although adding a structured cognitive component was of no added benefit and led to higher health care costs.119,122 A multidisciplinary, 6-month group therapy program demonstrated improvement that lasted more than 1 year but has not been studied in a formal, controlled manner.123 Most patients with FM use alternative or complementary therapies. Their use correlated with socioeconomic status and the duration of symptoms, but there was no evidence of improved outcome.124 Many therapeutic modalities, such as physical therapy and trigger-point injections, are routinely used in FM but may be virtually impossible to evaluate in rigorous, controlled studies.125
What are the outcome and prognosis?
In outcome studies,126-129 the symptoms of FM remain stable over time. In the longest follow-up study from a single medical center,126,129 29 patients with FM were surveyed 1, 3, and 14 years after diagnosis. Although 16 (55%) of 29 patients still reported moderate to severe pain, fatigue, and sleep disturbances, 19 (66%) of 29 felt better than when first diagnosed 14 years earlier, and 16 (73%) of 22 thought that their symptoms interfered little, if at all, with work.129
In a multicenter outcome study,130,131 538 patients were prospectively observed for 7 consecutive years. Patients with FM averaged 10 outpatient medical visits per year and used a mean of 3 FM-related drugs. The mean yearly per patient cost in 1996 dollars was $2274, similar to costs for the treatment of osteoarthritis.130 The major contributors to cost were hospital admission and drugs. Nonsteroidal anti-inflammatory drugs were most commonly prescribed, even though they have not been of proven efficacy.96 Comorbidities, disability, and disease severity correlated with total costs. Even in these rheumatology centers with a special interest in FM, there was only slight improvement in health satisfaction and no significant change (P=.66) in functional disability or symptoms during the 7 years.131 Sixty percent of these patients rated their health as fair or poor. Among the 6 centers, there were marked differences in symptom severity and outcome. Correlations between the symptoms at first and last assessment were high (r=0.82).
In contrast, community-based studies of FM report a better overall outcome. In 1 report from Australia,132 25% of patients were in remission 2 years after the diagnosis. Another study133 demonstrated better outcome in patients with chronic pain observed by general practitioners than in those treated by specialists. These reports reflect the same trend that has been noted in patients with CFS, IBS, chronic widespread pain, and headaches. Persons in the community with chronic pain have better outcome than tertiary referral patients. Health care use and functional status are related more to premorbid and current psychosocial factors than to the core symptoms of the syndromes.
The issue of disability in FM is similar to that in any chronic pain disorder.134 Can pain cause disability? How can we measure pain and disability in conditions with no objective criteria? Patient-perceived work disability has been similar in FM and rheumatoid arthritis.132,133,135-138 No valid instruments are able to assess disability in patients with FM.139 Functional impairment has been documented in these patients.134 A number of factors were found74 to be independently associated with impaired function, including pain levels, self-assessed disability, pending litigation, education, sense of helplessness and coping ability, and psychological distress.
The issue of causation, especially in the workplace, has become especially contentious. A longitudinal multicenter survey140 of 1604 patients with FM found that 27% received at least 1 form of social security or other disability payments. Two thirds of patients were working. The likelihood of receiving disability pensions for FM reflects the current diagnostic interest as well as the status of insurers approving claims for chronic pain in specific countries.141 A "diagnosis" of FM in the workplace may promote disability by fostering the notion of "soft tissue injury." Evidence to determine whether there is a causal relationship between trauma and FM is currently inadequate.134,142 Until such a relationship is established, the terms "posttraumatic" or "secondary" FM should not be used.143
A person's perception of the relationship of FM symptoms to trauma has an important effect on outcome. Those who identify trauma as causal have greater levels of pain, more interference with daily activities, and greater disability than those with FM of an idiopathic onset.75,76 The perception of physical trauma as a precipitating event is also a greater determinant of disability than that of emotional trauma.45 Patients who met criteria for CFS and FM had particularly high rates (51%) of unemployment.144
An even more contentious issue is whether financial compensation should be awarded to patients with disability due to FM. An individual physician may choose to be an advocate for a patient with FM seeking such compensation, provided the patient meets diagnostic criteria and that symptom severity, activity level, work capacity, psychosocial factors, and current work status support the claim. Disability should not be based on the diagnosis of FM but, rather, on an evaluation of the effect of chronic pain and distress on the person.134 Job dissatisfaction, work disability, and litigation however, have an adverse effect on outcome in FM.74 This situation is similar to that of other idiopathic pain disorders, sometimes related to trauma or certain occupations.4,145 Therefore, it is the responsibility of health care professionals to minimize disability in FM and to encourage patients to continue to be as active as possible.
Is the diagnosis of fm useful?
Every specialty of medicine has assigned diagnostic labels to chronic illness in which causation and pathogenesis are not understood. Fibromyalgia is simply a label to use when patients have chronic, unexplained diffuse pain. The classification criteria for FM have been validated in numerous clinic and population-based studies. Interobserver reliability of tender point counts has been determined, and prevalence studies146,147 have been similar across international surveys. Some authors have been opposed to the name "FM," suggesting that it implies pathological abnormalities in muscle.148 In contrast to the older term, fibrositis, however, this label was chosen because it describes the 2 cardinal features of diffuse myalgias and tenderness in the fibrous soft tissues. Unless there is a better understanding of its pathogenic mechanisms, the term FM is as good as any other and is now internationally accepted.
Disorders that lack "objective markers" are usually considered to be functional, not "organic." This implies to some that the physical symptoms are manifestations of an emotional disorder. An alternative explanation is that the organic abnormalities are too subtle to be detected. A good example of this is migraine. Substantial clinical and laboratory features overlap in migraine and FM.31,34 Olesen149 recently admonished: "It is time for many practitioners of medicine to change their views and to acknowledge that migraine is a neurobiologic, not a psychogenic disorder." Even the most prominent skeptics would agree that millions of people have widespread, idiopathic chronic pain and fatigue.
The more perplexing issue is whether the diagnostic label of FM helps patients and adds to our understanding of chronic pain. The titles of recent articles published by rheumatologists emphasize the unease within the medical community: "Fibromyalgia: Out of Control?"150; "Fibromyalgia: La Maladie Est Morte: Vive le Malade"151; "Fibromyalgia, Chronic Fatigue, and Other Iatrogenic Diagnostic Algorithms"152; and "Fibromyalgia: Scourge of Humankind or Bane of a Rheumatologist's Existence?"153 These authors suggest that a diagnostic label drives the illness-disease paradigm, promoting sickness behavior and somatization in people suffering normal aches and distress.4,151 Others comment that patients with FM exaggerate their disability and pain, "in contradistinction to patients with genuine rheumatologic disease, such as rheumatoid arthritis."3(p595) This is the age-old anachronism that illnesses lacking objectivity are not genuine.
The diagnostic label itself does not promote sickness behavior unless it is used as a substitute for patient information and education. Rather, it reassures worried people that a degenerative disease is not present. Patients can concentrate on getting better rather than getting a diagnosis or searching for a cause and cure. Physicians can confidently predict that FM, as well as CFS, migraine, and IBS, are "safe" diagnoses—unlikely to change over time.154
In 1 report,155 90% of patients believed that a diagnosis of CFS was the most helpful factor in managing their symptoms. In contrast, 70% of general practitioners were reluctant to diagnose CFS because of scientific uncertainty and concern that the diagnosis would become a self-fulfilling prophecy.155 The long-term prognosis of IBS is strongly influenced by a positive physician-patient interaction that provides a discussion of diagnosis and treatment.154
Most patients with FM have had symptoms for 5 to 7 years before a diagnosis is made.1,8 Once FM is diagnosed, the number of hospital admissions and health care use decreases.156 The recognition of FM as a major contributor to the symptoms of concurrent rheumatic conditions, such as rheumatoid arthritis and SLE, has changed the approach to treatment and provided renewed interest in the important psychosocial aspects of the common rheumatic disorders.25,26 That FM often mimics systemic diseases such as SLE and Lyme disease has led to more careful and cost-effective guidelines regarding nonspecific diagnostic tests and inappropriate treatment.28 In general, the diagnostic label of FM has been enabling rather than disabling.
Fibromyalgia is a clinical syndrome. It is not a disease but, rather, a common group of symptoms that can be reliably identified in medical clinics and in the community. Although FM is most recognizable when there are no concurrent medical or psychiatric illnesses, it is important to diagnose it when it is associated with rheumatic diseases or Lyme disease because treatment will be different. It may not be important to differentiate FM from associated disorders such as CFS, IBS, or idiopathic chronic pain. Most patients with FM do not have a current psychiatric illness. There is a higher incidence of psychiatric disorders in patients in tertiary referral centers who have FM than in community controls with FM. Current and past episodes of psychological distress and psychiatric diagnoses are directly related to health care use in patients with FM. There is no single etiologic factor, although physical and emotional trauma and infections may trigger FM. It is best thought of as a disorder of pain perception, presumably involving neurohormonal dysregulation. Physicians and patients need to understand that the medical model of specific cause and effect may not apply to disorders such as FM. There is no single highly effective treatment. Medicines that affect pain perception, sleep, and mood have been useful and should be integrated with activity, exercise, and educational programs. Most patients with FM observed in tertiary referral centers report little change in their symptoms over time. The outcome is directly related to psychosocial factors, including past and current psychological distress and work status or disability issues. As with any chronic illness, patients in the community do better than those observed in specialty clinics. Ten percent to 30% of patients describe being work impaired from FM. Physicians should discourage inactivity and disability because, if these are prolonged, there is an adverse effect on prognosis. Finally, patients have found a diagnostic label to be reassuring, and the diagnosis has decreased costly testing and health care use. The concern that a diagnostic label will enhance the medicalization of common symptoms is a realistic one, but when chronic pain or fatigue or mood disturbances become so prominent that they interfere with daily activities, it is appropriate to identify these abnormal levels of suffering as a syndrome that requires medical attention.
Fibromyalgia was described in the early 1800s but has only recently emerged as a common musculoskeletal diagnosis. Its recognition as a discrete syndrome is largely due to the acceptance of subjective classification criteria of uniform symptoms present in a large number of people. Researchers and policymakers should focus on the biopsychological influences that determine which persons in the community with FM become patients and seek medical help.
Accepted for publication August 6, 1998.
Reprints: Don L. Goldenberg, MD, Department of Rheumatology, Newton-Wellesley Hospital, 2000 Washington St, Suite 304, Newton, MA 02162.
1.Goldenberg
DL Fibromyalgia syndrome: an emerging but controversial condition.
JAMA. 1987;2572782- 2787
Google ScholarCrossref 2.Carette
S Fibromyalgia 20 years later: what have we really accomplished?
J Rheumatol. 1995;22590- 594
Google Scholar 3.Bohr
T Problems with myofascial pain syndrome and fibromyalgia syndrome.
Neurology. 1996;46593- 597
Google ScholarCrossref 4.Hadler
NM If you have to prove that you are ill, you can't get well: the object lesson of fibromyalgia.
Spine. 1996;212397- 2400
Google ScholarCrossref 5.Croft
PRigby
ASBoswell
RSchollum
JSilman
A The prevalence of chronic widespread pain in the general population.
J Rheumatol. 1993;20710- 713
Google Scholar 6.Wolfe
FRoss
KAnderson
JRussell
IJHebert
L The prevalence and characteristics of fibromyalgia in the general population.
Arthritis Rheum. 1995;3819- 28
Google ScholarCrossref 8.Wolfe
FSmythe
HAYunus
MB
et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: report of the Multicenter Criteria Committee.
Arthritis Rheum. 1990;33160- 172
Google ScholarCrossref 9.Yunus
MMasi
ATCalabro
JJMiller
KAFeigenbaum
SL Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls.
Semin Arthritis Rheum. 1981;11151- 171
Google ScholarCrossref 10.Wolfe
FHawley
DJCathey
MACaro
XRussell
IJ Fibrositis: symptom frequency and criteria for diagnosis: an evaluation of 291 rheumatic disease patients and 58 normal individuals.
J Rheumatol. 1985;121159- 1163
Google Scholar 11.Croft
PSchollum
JSilman
A Population study of tender point counts and pain as evidence of fibromyalgia.
BMJ. 1994;309696- 699
Google ScholarCrossref 12.Marder
WDMeenan
RFFelson
DT
et al. The present and future adequacy of rheumatology manpower: a study of health care needs and physician supply [editorial].
Arthritis Rheum. 1991;341209- 1217
Google ScholarCrossref 13.Wolfe
FCathey
MA The epidemiology of tender points: a prospective study of 1520 patients.
J Rheumatol. 1985;121164- 1168
Google Scholar 14.Simms
RWGoldenberg
DLFelson
DTMason
JH Tenderness in 75 anatomic sites: distinguishing fibromyalgia patients from controls.
Arthritis Rheum. 1988;31182- 187
Google ScholarCrossref 16.Tunks
EMcCain
GAHart
LE
et al. The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls.
J Rheumatol. 1995;22944- 952
Google Scholar 17.Jacobs
JWGeenen
Rvan der Heide
ARasker
JJBijlsma
JW Are tender point scores assessed by manual palpation in fibromyalgia reliable? an investigation into the variance of tender point scores.
Scand J Rheumatol. 1995;24243- 247
Google ScholarCrossref 18.Croft
PBurt
JSchollum
JThomas
EMacFarlane
GSilman
A More pain, more tender points: is fibromyalgia just one end of a continuous spectrum?
Ann Rheum Dis. 1996;55482- 485
Google ScholarCrossref 19.Wolfe
F The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic.
Ann Rheum Dis. 1997;56268- 271
Google ScholarCrossref 21.Callahan
LFPincus
T A clue from a self-report questionnaire to distinguish rheumatoid arthritis from noninflammatory diffuse musculoskeletal pain: the P-VAS:D-ADL ratio.
Arthritis Rheum. 1990;331317- 1322
Google ScholarCrossref 22.Glazier
RHDalby
DMBadley
EMHawker
GABell
MJBuchbinder
R Determinants of physician confidence in the primary care management of musculoskeletal disorders.
J Rheumatol. 1996;23351- 356
Google Scholar 24.Wolfe
FCathey
MA Prevalence of primary and secondary fibrositis.
J Rheumatol. 1983;10965- 968
Google Scholar 25.Gladman
DDUrowitz
MBGough
JMacKinnon
A Fibromyalgia is a major contributor to quality of life in lupus.
J Rheumatol. 1997;242145- 2148
Google Scholar 26.Middleton
GDMcFarlin
JELipsky
PE The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus.
Arthritis Rheum. 1994;371181- 1188
Google ScholarCrossref 28.Sigal
LH The Lyme disease controversy: social and financial costs of misdiagnosis and mismanagement.
Arch Intern Med. 1996;1561493- 1500
Google ScholarCrossref 29.Lightfoot
RW
JrLuft
BJRahn
DW
et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: a cost-effectiveness analysis.
Ann Intern Med. 1993;119503- 509
Google ScholarCrossref 30.Calvo-Alen
JBastian
HMStraaton
KVBurgard
SLMikhail
ISAlarcon
GS Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center.
Arthritis Rheum. 1995;381475- 1484
Google ScholarCrossref 31.Hudson
JIGoldenberg
DLPope
HG
JrKeck
PE
JrSchlesinger
L Comorbidity of fibromyalgia with medical and psychiatric disorders.
Am J Med. 1992;92363- 367
Google ScholarCrossref 32.Triadafilopoulos
GSimms
RWGoldenberg
DL Bowel dysfunction in fibromyalgia syndrome.
Dig Dis Sci. 1991;3659- 64
Google ScholarCrossref 33.Goldenberg
DLSimms
RWGeiger
AKomaroff
AL High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice.
Arthritis Rheum. 1990;33381- 387
Google ScholarCrossref 34.Nicolodi
MSicuteri
F Fibromyalgia and migraine, two faces of the same mechanism: serotonin as the common clue for pathogenesis and therapy.
Adv Exp Med Biol. 1996;398373- 379
Google Scholar 35.Hudson
JIPope
HG The concept of affective spectrum disorder: relationship to fibromyalgia and other syndromes of chronic fatigue and chronic muscle pain.
Baillieres Clin Rheumatol. 1994;8839- 856
Google ScholarCrossref 36.Goldenberg
DL A review of the role of tricyclic medications in the treatment of fibromyalgia syndrome.
J Rheumatol Suppl. 1989;19137- 139
Google Scholar 37.Goldenberg
DLMayskiy
MMossey
CJRuthazer
RSchmid
C A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia.
Arthritis Rheum. 1996;391852- 1859
Google ScholarCrossref 38.Ahles
TAKhan
SAYunus
MBSpiegel
DAMasi
AT Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis, and subjects without pain: a blind comparison of
DSM-III diagnoses.
Am J Psychiatry. 1991;1481721- 1726
Google Scholar 39.Yunus
MBAhles
TAAldag
JAMasi
AT Relationship of clinical features with psychological status in primary fibromyalgia.
Arthritis Rheum. 1991;3415- 21
Google ScholarCrossref 40.Hudson
JIPope
HG
Jr Fibromyalgia and psychopathology: is fibromyalgia a form of "affective spectrum disorder?"
J Rheumatol Suppl. 1989;1915- 22
Google Scholar 41.Yunus
MB Psychological aspects of fibromyalgia syndrome: a component of the dysfunctional spectrum syndrome.
Baillieres Clin Rheumatol. 1994;8811- 837
Google ScholarCrossref 42.Hudson
JIPope
HG
Jr Does childhood sexual abuse cause fibromyalgia?
Arthritis Rheum. 1995;38161- 163
Google ScholarCrossref 43.Boisset-Pioro
MHEsdaile
JMFitzcharles
MA Sexual and physical abuse in women with fibromyalgia syndrome.
Arthritis Rheum. 1995;38235- 241
Google ScholarCrossref 44.Drossman
DALeserman
JNachman
G
et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders.
Ann Intern Med. 1990;113828- 833
Google ScholarCrossref 45.Aaron
LABradley
LAAlarcon
GS
et al. Perceived physical and emotional trauma as precipitating events in fibromyalgia: associations with health care seeking and disability status but not pain severity.
Arthritis Rheum. 1997;40453- 460
Google ScholarCrossref 46.Aaron
LABradley
LAAlarcon
GS
et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness.
Arthritis Rheum. 1996;39436- 445
Google ScholarCrossref 47.Drossman
DAMcKee
DCSandler
RS
et al. Psychosocial factors in the irritable bowel syndrome: a multivariate study of patients and nonpatients with irritable bowel syndrome.
Gastroenterology. 1988;95701- 708
Google Scholar 48.Mountz
JMBradley
LAModell
JG
et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels.
Arthritis Rheum. 1995;38926- 938
Google ScholarCrossref 49.Aaron
LABradley
LAAlexander
MT
et al. Prediction of health-care seeking for fibromyalgia (FM) symptoms among community residents with FM [abstract].
Arthritis Rheum. 1995;38
((suppl))
S230
Google Scholar 50.Alexander
RWAlexander
MTBradley
LA
et al. Negative affectivity (NA) is associated with pain perception in patients with fibromyalgia (FM): support for sensory decision theory (SDT) model [abstract].
Arthritis Rheum. 1995;38
((suppl))
S270
Google Scholar 51.Bradley
LAAlarcón
GSAlexander
RW
et al. Abnormal central processing of dolorimeter stimuli in patients and community residents with fibromyalgia (FM): one year reliability [abstract].
Arthritis Rheum. 1995;38
((suppl))
S318
Google ScholarCrossref 52.Yunus
MDKalyan-Raman
UPMasi
ATAldag
JC Electromicroscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study.
J Rheumatol. 1989;1697- 101
Google Scholar 53.Simms
RWRoy
SHHrovat
M
et al. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism.
Arthritis Rheum. 1994;37794- 800
Google ScholarCrossref 54.Pillemer
SRBradley
LACrofford
LJMoldofsky
HChrousos
GP Conference summary: the neuroscience and endocrinology of fibromyalgia.
Arthritis Rheum. 1997;401928- 1939
Google ScholarCrossref 55.McDermid
AJRollman
GBMcCain
GA Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification.
Pain. 1996;66133- 144
Google ScholarCrossref 56.Bendtsen
LNorregaard
JJensen
ROlesen
J Evidence of qualitatively altered nociception in patients with fibromyalgia.
Arthritis Rheum. 1997;4098- 127
Google ScholarCrossref 57.Arroyo
JFCohen
ML Abnormal responses to electrocutaneous stimulation in fibromyalgia.
J Rheumatol. 1993;201925- 1931
Google Scholar 58.Kosek
EEkholm
JHansson
P Increased pressure pain sensibility in fibromyalgia patients is located deep in the skin but not restricted to muscle tissue.
Pain. 1995;63335- 339
Google ScholarCrossref 59.Kosek
EEkholm
JHansson
P Modulation of pressure pain thresholds during and following isometric contraction in patients with fibromyalgia and in healthy controls.
Pain. 1996;64415- 423
Google ScholarCrossref 60.Russell
IJOrr
MDLittman
B
et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome.
Arthritis Rheum. 1994;371593- 1601
Google ScholarCrossref 61.Russell
IJVaeroy
HJavors
MNyberg
F Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis.
Arthritis Rheum. 1992;35550- 556
Google ScholarCrossref 62.Drewes
AMGade
JNielsen
KDBjerregard
KTaagholt
SJSvendsen
L Clustering of sleep electroencephalographic patterns in patients with the fibromyalgia syndrome.
Br J Rheumatol. 1995;341151- 1156
Google ScholarCrossref 63.Branco
JAtalaia
APaiva
T Sleep cycles and alpha-delta sleep in fibromyalgia syndrome.
J Rheumatol. 1994;211113- 1117
Google Scholar 64.Roizenblatt
STufik
SGoldenberg
JPinto
LRHilario
MOFeldman
D Juvenile fibromyalgia: clinical and polysomnographic aspects.
J Rheumatol. 1997;24579- 585
Google Scholar 65.May
KPWest
SGBaker
MREverett
DW Sleep apnea in male patients with the fibromyalgia syndrome.
Am J Med. 1993;94505- 508
Google ScholarCrossref 66.Yunus
MBAldag
JC Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study.
BMJ. 1996;3121339
Google ScholarCrossref 67.MacFarlane
JGShahal
BMously
CMoldofsky
H Periodic K-alpha sleep EEG activity and periodic limb movements during sleep: comparisons of clinical features and sleep parameters.
Sleep. 1996;19200- 204
Google Scholar 68.Griep
ENBoersma
JWde Kloet
ER Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome.
J Rheumatol. 1993;20469- 474
Google Scholar 69.Crofford
LJPillemer
SRKalogeras
KT
et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia.
Arthritis Rheum. 1994;371583- 1592
Google ScholarCrossref 70.Bennett
RMClark
SRCampbell
SMBurckhardt
CS Low levels of somatomedin-C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain.
Arthritis Rheum. 1992;351113- 1116
Google ScholarCrossref 71.Bennett
RMCook
DMClark
SRBurckhardt
CSCampbell
SM Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia.
J Rheumatol. 1997;241384- 1389
Google Scholar 72.Bou-Holaigah
IRowe
PCKan
JCalkins
H The relationship between neurally mediated hypotension and the chronic fatigue syndrome.
JAMA. 1995;274961- 967
Google ScholarCrossref 73.Bou-Holaigah
ICalkins
HFlynn
JA
et al. Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia.
Clin Exp Rheumatol. 1997;15239- 246
Google Scholar 74.Goldenberg
DLMossey
CJSchmid
CH A model to assess severity and impact of fibromyalgia.
J Rheumatol. 1995;222313- 2318
Google Scholar 75.Greenfield
SFitzcharles
MAEsdaile
JM Reactive fibromyalgia syndrome.
Arthritis Rheum. 1992;35678- 681
Google ScholarCrossref 76.Turk
DCOkifuji
ASinclair
JDStarz
TW Pain, disability, and physical functioning in subgroups of patients with fibromyalgia.
J Rheumatol. 1996;231255- 1262
Google Scholar 77.Berg
AMNaides
SJSimms
RW Established fibromyalgia syndrome and parvovirus B19 infection.
J Rheumatol. 1993;201941- 1943
Google Scholar 80.Hsu
VMPatella
SJSigal
LH "Chronic Lyme disease" as the incorrect diagnosis in patients with fibromyalgia.
Arthritis Rheum. 1993;361493- 1500
Google ScholarCrossref 81.Smythe
HA The C6-7 syndrome: clinical features and treatment response.
J Rheumatol. 1994;211520- 1526
Google Scholar 82.Gedalia
APress
JKlein
MBuskila
D Joint hypermobility and fibromyalgia in schoolchildren.
Ann Rheum Dis. 1993;52494- 496
Google ScholarCrossref 83.Hudson
NStarr
MREsdaile
JMFitzcharles
MA Diagnostic associations with hypermobility in rheumatology patients.
Br J Rheumatol. 1995;341157- 1161
Google ScholarCrossref 84.Smythe
HALee
DRush
PBuskila
D Tender shins and steroid therapy.
J Rheumatol. 1991;181568- 1572
Google Scholar 85.Buskila
DNeumann
LVaisberg
GAlkalay
DWolfe
F Increased rates of fibromyalgia following cervical spine injury: a controlled study of 161 cases of traumatic injury.
Arthritis Rheum. 1997;40446- 452
Google ScholarCrossref 86.Buskila
DNeumann
LHazanov
ICarmi
R Familial aggregation in the fibromyalgia syndrome.
Semin Arthritis Rheum. 1996;26605- 611
Google ScholarCrossref 87.Simms
RWFelson
DTGoldenberg
DL Development of preliminary criteria for response to treatment in fibromyalgia syndrome.
J Rheumatol. 1991;181558- 1563
Google Scholar 88.Burckhardt
CSClark
SRBennett
RM The fibromyalgia impact questionnaire: development and validation.
J Rheumatol. 1991;18728- 733
Google Scholar 89.White
KPHarth
M An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS).
Pain. 1996;64211- 219
Google ScholarCrossref 90.Hewett
JEBuckelew
SPJohnson
JCShaw
SEHuyser
BFu
YZ Selection of measures suitable for evaluating change in fibromyalgia clinical trials.
J Rheumatol. 1995;222307- 2312
Google Scholar 91.Carette
SOakson
GGuimont
CSteriade
M Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia.
Arthritis Rheum. 1995;381211- 1217
Google ScholarCrossref 92.Jacobs
JWRasker
JJvan der Heide
A
et al. Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia.
Arthritis Care Res. 1996;9105- 111
Google ScholarCrossref 93.Simms
RW Controlled trials of therapy in fibromyalgia syndrome.
Baillieres Clin Rheumatol. 1994;8917- 934
Google ScholarCrossref 94.Jaeschke
RAdachi
JGuyatt
GKeller
JWong
B Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials.
J Rheumatol. 1991;18447- 451
Google Scholar 95.Carette
SMcCain
GABell
DAFam
AG Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study.
Arthritis Rheum. 1986;29655- 659
Google ScholarCrossref 96.Goldenberg
DLFelson
DTDinerman
H A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia.
Arthritis Rheum. 1986;291371- 1377
Google ScholarCrossref 97.Bennett
RMGatter
RACampbell
SMAndrews
RPClark
SRScarola
JA A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study.
Arthritis Rheum. 1988;311535- 1542
Google ScholarCrossref 98.Godfrey
RG A guide to the understanding and use of antidepressants in the overall management of fibromyalgia and other chronic pain syndromes.
Arch Intern Med. 1996;1561047- 1052
Google ScholarCrossref 99.McCain
GABell
DAMai
FMHalliday
PD A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia.
Arthritis Rheum. 1988;311135- 1141
Google ScholarCrossref 100.Scudds
RAJanzen
VDelaney
G
et al. The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial.
Pain. 1995;6269- 77
Google ScholarCrossref 101.Ferraccioli
GGhirelli
LScita
F
et al. EMG-biofeedback training in fibromyalgia syndrome.
J Rheumatol. 1987;14820- 825
Google Scholar 102.Haanen
HCMHoenderdos
HTWvan Romunde
LKJ
et al. Controlled trial of hypnotherapy in the treatment of refractory fibromyalgia.
J Rheumatol. 1991;1872- 75
Google Scholar 103.Deluze
CBosia
LZirbs
AChantraine
AVischer
TL Electroacupuncture in fibromyalgia: results of a controlled trial.
BMJ. 1992;3051249- 1252
Google ScholarCrossref 104.Carette
JBell
MJReynolds
WJ
et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial.
Arthritis Rheum. 1994;3732- 40
Google ScholarCrossref 105.Caruso
ISarzi Puttini
PCBoccassini
L
et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome.
J Int Med Res. 1987;15154- 159
Google Scholar 106.Wolfe
FCathey
MAHawley
DJ A double-blind placebo controlled trial of fluoxetine in fibromyalgia.
Scand J Rheumatol. 1994;23255- 259
Google ScholarCrossref 107.Norregaard
JVolkmann
HDanneskiold-Samsoe
B A randomized controlled trial of citalopram in the treatment of fibromyalgia.
Pain. 1995;61445- 449
Google ScholarCrossref 108.Quijada-Carrera
JValenzuela-Castano
APovedano-Gomez
J
et al. Comparison of tenoxicam and bromazepan [sic] in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.
Pain. 1996;65221- 225
Google ScholarCrossref 109.Russell
IJFletcher
EMMichalek
JEMcBroom
PCHester
GG Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study.
Arthritis Rheum. 1991;34552- 560
Google ScholarCrossref 110.Yunus
MBMasi
ATAldag
JC Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial [published erratum appears in
J Rheumatol. 1989;16:855].
J Rheumatol. 1989;16527- 532
Google Scholar 111.Russell
IJMichalek
JDFlechas
JDAbraham
GE Treatment of fibromyalgia syndrome with Super Malic
®: a randomized, double blind, placebo controlled, crossover pilot study.
J Rheumatol. 1995;22953- 958
Google Scholar 112.Pearl
SJLue
FMacLean
AWHeslegrave
RJReynolds
WJMoldofsky
H The effects of bright light treatment on the symptoms of fibromyalgia.
J Rheumatol. 1996;23896- 902
Google Scholar 113.Volkmann
HNorregaard
JJacobsen
SDanneskiold-Samsoe
BKnoke
GNehrdich
D Double-blind, placebo-controlled cross-over study of intravenous
S-adenosyl-L-methionine in patients with fibromyalgia.
Scand J Rheumatol. 1997;26206- 211
Google ScholarCrossref 114.Martin
LNutting
AMacIntosh
BREdworthy
SMButterwick
DCook
J An exercise program in the treatment of fibromyalgia.
J Rheumatol. 1996;231050- 1053
Google Scholar 115.Wigers
SHStiles
TCVogal
PA Effects of aerobic exercise versus stress management treatment in fibromyalgia: a 4.5 year prospective study.
Scand J Rheumatol. 1996;2577- 86
Google ScholarCrossref 116.Petrie
KMoss-Morris
RWeinman
J The impact of catastrophic beliefs on functioning in chronic fatigue syndrome.
J Psychosom Res. 1995;3931- 37
Google ScholarCrossref 117.Wessely
SChalder
THirsch
SWallace
PWright
D Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting.
Am J Psychiatry. 1996;1531050- 1059
Google Scholar 118.White
KPNielson
WR Cognitive behavioral treatment of fibromyalgia syndrome: a follow-up assessment.
J Rheumatol. 1995;22717- 721
Google Scholar 119.Vlaeyen
JWSTeeken-Gruben
NJGGoossens
MEJB
et al. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial, I: clinical effects.
J Rheumatol. 1996;231237- 1245
Google Scholar 120.Butler
SChalder
TRon
MWessely
S Cognitive behaviour therapy in chronic fatigue syndrome.
J Neurol Neurosurg Psychiatry. 1991;54153- 158
Google ScholarCrossref 121.Goldenberg
DLKaplan
KHNadeau
MGBrodeur
CSmith
SSchmid
CH A controlled study of a stress-reduction, cognitive-behavioral treatment program in fibromyalgia.
J Musculoskeletal Pain. 1994;253- 66
Google ScholarCrossref 122.Goossens
MEJBRutten-van Mölken
MPMHLeidl
RMBos
SGPMVlaeyen
JWSTeeken-Gruben
NJG Cognitive-educational treatment of fibromyalgia: a randomized clinical trial, II: economic evaluation.
J Rheumatol. 1996;231246- 1254
Google Scholar 123.Bennett
RMBurckhardt
CSClark
SRO'Reilly
CAWiens
ANCampbell
SM Group treatment of fibromyalgia: a 6 month outpatient program.
J Rheumatol. 1996;23521- 528
Google Scholar 124.Fitzcharles
MAEsdaile
JM Nonphysician practitioner treatments and fibromyalgia syndrome.
J Rheumatol. 1997;24937- 940
Google Scholar 125.Hong
CZHsueh
TC Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia.
Arch Phys Med Rehabil. 1996;771161- 1166
Google ScholarCrossref 127.Norregaard
JBülow
PMPrescott
EJacobsen
SDanneskiold-Samsoe
B A four-year follow-up study in fibromyalgia: relationship to chronic fatigue syndrome.
Scand J Rheumatol. 1993;2235- 38
Google ScholarCrossref 128.Ledingham
JDoherty
SDoherty
M Primary fibromyalgia syndrome: an outcome study.
Br J Rheumatol. 1993;32139- 142
Google ScholarCrossref 129.Kennedy
MFelson
DT A prospective long-term study of fibromyalgia syndrome.
Arthritis Rheum. 1996;39682- 685
Google ScholarCrossref 130.Wolfe
FAnderson
JHarkness
D
et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia.
Arthritis Rheum. 1997;401560- 1570
Google ScholarCrossref 131.Wolfe
FAnderson
JHarkness
D
et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study.
Arthritis Rheum. 1997;401571- 1579
Google ScholarCrossref 132.Granges
GZilko
PLittlejohn
GO Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis.
J Rheumatol. 1994;21523- 529
Google Scholar 133.Crook
JWeir
RTunks
E An epidemiological follow-up survey of persistent pain sufferers in a group family practice and specialty pain clinic.
Pain. 1989;3649- 61
Google ScholarCrossref 135.Wigers
SH Fibromyalgia outcome: the predictive values of symptom duration, physical activity, disability pension, and critical life events: a 4.5 year prospective study.
J Psychosom Res. 1996;41235- 243
Google ScholarCrossref 136.Hawley
DJWolfe
FCathey
MA Pain, functional disability, and psychological status: a 12-month study of severity in fibromyalgia.
J Rheumatol. 1988;151551- 1556
Google Scholar 137.Hawley
DJWolfe
F Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients.
J Rheumatol. 1991;181552- 1557
Google Scholar 138.Burckhardt
CSClark
SRBennett
RM Fibromyalgia and quality of life: a comparative analysis.
J Rheumatol. 1993;20475- 479
Google Scholar 139.Mannerkorpi
KEkdahl
C Assessment of functional limitation and disability in patients with fibromyalgia.
Scand J Rheumatol. 1997;264- 13
Google ScholarCrossref 140.Wolfe
FAnderson
JHarkness
D
et al. Work and disability status of persons with fibromyalgia.
J Rheumatol. 1997;241171- 1178
Google Scholar 141.Bruusgaard
DEvensen
ARBjerkedal
T Fibromyalgia: a new cause for disability pension.
Scand J Soc Med. 1993;21116- 119
Google Scholar 142.Bennett
RM Fibromyalgia and the disability dilemma: a new era in understanding a complex, multidimensional pain syndrome.
Arthritis Rheum. 1996;391627- 1634
Google ScholarCrossref 143.Wolfe
FAarflot
TBruusgaard
D
et al. Fibromyalgia and disability: report of the Moss International Working Group on medico-legal aspects of chronic widespread musculoskeletal pain complaints and fibromyalgia.
Scand J Rheumatol. 1995;24112- 118
Google ScholarCrossref 144.Bombardier
CHBuchwald
D Chronic fatigue, chronic fatigue syndrome, and fibromyalgia: disability and health-care use.
Med Care. 1996;34924- 930
Google ScholarCrossref 145.Littlejohn
G Medicolegal aspects of fibrositis syndrome.
J Rheumatol Suppl. 1989;19169- 173
Google Scholar 146.Mannerkorpi
KBurckhardt
CSBjelle
A Physical performance characteristics of women with fibromyalgia.
Arthritis Care Res. 1994;7123- 129
Google ScholarCrossref 147.Okifuji
ATurk
DCSinclair
JDStarz
TWMarcus
DA A standardized manual tender point survey, I: development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome.
J Rheumatol. 1997;24377- 383
Google Scholar 148.Bohr
TW Fibromyalgia syndrome and myofascial pain syndrome: do they exist?
Neurol Clin. 1995;13365- 384
Google Scholar 150.Gordon
DA Fibromyalgia: out of control? [editorial].
J Rheumatol. 1997;241247
Google Scholar 151.Hadler
NM Fibromyalgia: la maladie est morte: vive le malade.
J Rheumatol. 1997;241250- 1252
Google Scholar 152.Hadler
NM Fibromyalgia, chronic fatigue, and other iatrogenic diagnostic algorithms.
Postgrad Med. 1997;102161- 177
Google ScholarCrossref 153.Solomon
DHLiang
MH Fibromyalgia: scourge of humankind or bane of a rheumatologist's existence?
Arthritis Rheum. 1997;401553- 1555
Google ScholarCrossref 154.Owens
DMNelson
DKTalley
NJ The irritable bowel syndrome: long-term prognosis and the physician-patient interaction.
Ann Intern Med. 1995;122107- 122
Google ScholarCrossref 155.Woodward
RVBroom
DHLegge
DG Diagnosis in chronic illness: disabling or enabling: the case of chronic fatigue syndrome.
J R Soc Med. 1995;88325- 329
Google Scholar 156.Cathey
MAWolfe
FKleinheksel
SMHawley
DJ Socioeconomic impact of fibrositis: a study of 81 patients with primary fibrositis.
Am J Med. 1986;8178- 84
Google ScholarCrossref